MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Total Liabilities 2011-2026 | NVTA
Annual Total Liabilities Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.85 B | 1.94 B | 1.45 B | 402 M | 121 M | 89.3 M | 31.6 M | 18.3 M | 212 M | 90.4 M | 38.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 B | 18.3 M | 568 M |
Quarterly Total Liabilities Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.62 B | 1.72 B | 1.73 B | 1.85 B | 1.87 B | 1.9 B | 1.92 B | 1.94 B | 1.96 B | 2.34 B | 1.5 B | 1.45 B | 1.45 B | 1.45 B | 1.45 B | 402 M | 402 M | 402 M | 402 M | 121 M | 121 M | 121 M | 121 M | 89.3 M | 89.3 M | 89.3 M | 89.3 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 10 M | 10 M | 10 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.34 B | 10 M | 740 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.32 B | $ 114.78 | -0.61 % | $ 34.9 B |  USA |
|
Biodesix
BDSX
|
76.4 M | $ 15.7 | 4.18 % | $ 2.04 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.15 | -0.83 % | $ 4.94 M | USA |
 |
BioNano Genomics
BNGO
|
29.2 M | $ 1.16 | -3.33 % | $ 6.32 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
433 M | $ 16.33 | 0.8 % | $ 176 M |  China |
 |
CareDx, Inc
CDNA
|
110 M | $ 18.12 | -1.04 % | $ 966 M | USA |
 |
Celcuity
CELC
|
366 M | $ 114.33 | 1.5 % | $ 5.35 B | USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 166.88 | -4.03 % | $ 8.27 B | USA |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 25.0 | 0.64 % | $ 694 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
Danaher Corporation
DHR
|
31.8 B | $ 191.23 | 0.06 % | $ 136 B | USA |
 |
DexCom
DXCM
|
3.59 B | $ 63.01 | 1.26 % | $ 24.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 16.56 | -1.55 % | $ 501 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 90.84 | -3.19 % | $ 11.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 111.1 | -2.71 % | $ 9.16 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.92 | -1.92 % | $ 8.49 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 126.95 | -0.34 % | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | China |
 |
IQVIA Holdings
IQV
|
23.3 B | $ 169.58 | -2.12 % | $ 29.2 B | USA |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 274.35 | 0.23 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 75.67 | -0.57 % | $ 5.11 B | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 494.14 | -0.84 % | $ 14.3 B | USA |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 256.28 | -0.29 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.76 | 0.11 % | $ 441 M | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
ENDRA Life Sciences
NDRA
|
1.59 M | $ 4.57 | -2.46 % | $ 3.6 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 7.98 | -0.25 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 9.51 | 1.01 % | $ 2.06 B | USA |
 |
National Research Corporation
NRC
|
121 M | $ 17.43 | 1.6 % | $ 390 M | USA |
 |
Natera
NTRA
|
689 M | $ 204.77 | -1.54 % | $ 20.2 B | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.41 | 5.05 % | $ 423 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 27.02 | -0.33 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
6.76 M | $ 26.84 | 5.67 % | $ 43.1 M | USA |
 |
Personalis
PSNL
|
67.3 M | $ 6.64 | 0.84 % | $ 393 M | USA |
 |
RadNet
RDNT
|
2.4 B | $ 55.13 | 0.62 % | $ 4.15 B | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |